{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=34&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Phoenix",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 8145,
    "total_pages": 815,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=35&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=33&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T14:26:27.420Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07680868",
      "title": "Caris Chromoseq Data Collection",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases",
        "Myelodysplatic Syndromes",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Caris Chromoseq",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Caris Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-07",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07680868"
    },
    {
      "nct_id": "NCT00286455",
      "title": "Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Alogliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 329,
      "start_date": "2006-02",
      "completion_date": "2007-07",
      "has_results": true,
      "last_update_posted_date": "2012-02-03",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286455"
    },
    {
      "nct_id": "NCT06127043",
      "title": "A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Rosnilimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AnaptysBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2023-12-04",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Garden Grove, California • Lancaster, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06127043"
    },
    {
      "nct_id": "NCT06291376",
      "title": "Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy",
        "IgAN"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 584,
      "start_date": "2024-03-29",
      "completion_date": "2030-07-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 39,
      "location_summary": "Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06291376"
    },
    {
      "nct_id": "NCT01868516",
      "title": "Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "dexmecamylamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targacept Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1635,
      "start_date": "2013-05",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 125,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868516"
    },
    {
      "nct_id": "NCT01605084",
      "title": "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Optimized NRTI backbone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-06-30",
      "completion_date": "2014-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605084"
    },
    {
      "nct_id": "NCT02964338",
      "title": "A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Cluster Headache"
      ],
      "interventions": [
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 259,
      "start_date": "2017-01-17",
      "completion_date": "2018-07-18",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02964338"
    },
    {
      "nct_id": "NCT00676143",
      "title": "Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "bapineuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "50 Years to 88 Years"
      },
      "enrollment_count": 1100,
      "start_date": "2008-01",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2016-06-10",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 111,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676143"
    },
    {
      "nct_id": "NCT04870944",
      "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Midline Glioma, H3 K27-Altered",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Diffuse Midline Glioma, H3 K27-Altered",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspirate",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "FACT Complex-targeting Curaxin CBL0137",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 63,
      "start_date": "2022-01-28",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04870944"
    },
    {
      "nct_id": "NCT04031885",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2019-08-14",
      "completion_date": "2020-08-11",
      "has_results": true,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-10-19T14:26:27.420Z",
      "location_count": 55,
      "location_summary": "Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04031885"
    }
  ]
}